How to Buy Aclaris Therapeutics Stock
Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research.
Aclaris Therapeutics stock last closed at $1.24, up 0.81% from the previous day, and has decreased 86.85% in one year. It has underperformed other stocks in the Diagnostics & Research industry by 0.77 percentage points. Aclaris Therapeutics stock is currently +110.17% from its 52-week low of $0.59, and -88.85% from its 52-week high of $11.12.
As of Apr 19, 2024, there are 70.93M shares of ACRS outstanding. The market capitalization of ACRS is $87.95M. In the past 24 hours, 579,623 ACRS shares were traded.
How to Buy Aclaris Therapeutics Stock
Wondering how to invest in Aclaris Therapeutics stock? Here's how.
- Figure out where to buy Aclaris Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you choose where to buy Aclaris Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Research Aclaris Therapeutics stock: The Aclaris Therapeutics ticker symbol is ACRS. Is Aclaris Therapeutics stock a good investment? Should you buy shares of ACRS? How do ACRS's underlying business fundamentals look? Do top analysts think Aclaris Therapeutics is a good buy? Why has ACRS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if ACRS is a good stock to buy).
- Make your ACRS purchase: Decide if you will purchase ACRS shares at the current market price or use a limit order to buy ACRS shares at a given price.
- Get the latest news on your ACRS position: Create a watchlist to keep track of your position in Aclaris Therapeutics stock.
Step 1: Figure out where to buy Aclaris Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy ACRS shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Energy, New York to Hong Kong — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal details so you are able to buy ACRS today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to open a new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the best stock trading app, your next step is to transfer the money for your investment:
Check out the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Aclaris Therapeutics stock
After you have decided on the best place to buy Aclaris Therapeutics stock, it's absolutely critical to evaluate their stock prior to buying, so you can understand the risk as well as the upside.
Aclaris Therapeutics Metrics
Aclaris Therapeutics Due Diligence Checks
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ACRS's stock page.
Is ACRS stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ACRS's fair value.
Using relative valuations ratios:
- ACRS could be undervalued based on its P/B ratio of 0.56x, relative to Diagnostics & Research industry P/B ratio of 4.01x
You can do more valuation analysis on ACRS's stock here.
ACRS Financial Health Summary
Positive Financial Indicators:
- ACRS has a low debt to equity ratio of 0.26.
- There are more short-term assets than short-term liabilities on the ACRS balance sheet.
- Total ACRS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the ACRS balance sheet.
- ACRS has cash burn of 79634000. It has enough cash and short-term investments to cover this for at least one year.
Negative Financial Indicators:
- ACRS profit margin has gone up by 0.09 percentage points in the past year, but the company is still unprofitable.
- ACRS has $119.11M in cash and short term investments. This is not enough to cover its annual cash burn of $79.63M.
Do Wall Street analysts think it's a good time to buy Aclaris Therapeutics stock
Out of 2 sell side analysts who track ACRS, the consensus analyst rating on Aclaris Therapeutics is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Aclaris Therapeutics stock forecast page.
ACRS Technicals
ACRS Growth Metrics
Last year, ACRS revenue was $31.25M. During the last five year, ACRS's revenue has grown by 38.41% per year. This was faster than the Diagnostics & Research industry average of 12.94%.
Find out more about ACRS's earnings and revenue performance here.
Latest Insiders Trades at ACRS
In the last 12 months, executives and large shareholders at ACRS have sold more shares than they have bought.
Neal Walker, INTERIM PRESIDENT AND CEO of ACRS, was the latest ACRS insider to sell. They sold $4,062.24 worth of ACRS shares on Apr 1, 2024.
Learn more about who owns ACRS shares here.
Can I rely on ACRS as an income stream?
No, Aclaris Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your ACRS purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount limit, use a limit order.
Press the Open Trade button and your broker will execute your order.
If you need more assistance investing in stocks on eToro, click the helpful video below:
Step 6: Get the latest news on your ACRS position
Now that you own some ACRS stock, you'll want to keep up with your stock purchase.
Create a watchlist to get notified of the latest news about your ACRS stock.
ACRS Feed
How to Buy Stock in Aclaris Therapeutics
To reiterate, here are the 6 steps to buy stock in Aclaris Therapeutics:
- Figure out where to buy Aclaris Therapeutics stock
- Open your brokerage account
- Deposit funds into your investment account
- Research Aclaris Therapeutics stock
- Make your ACRS purchase
- Get the latest news on your ACRS position
If you need a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Aclaris Therapeutics, hit the button below to create your watchlist.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.